Oncology News & Perspectives

Featured Exclusive

​Philipp Tschandl, MD, PhD, and colleagues found that current artificial intelligence (AI) algorithms that use "deep learning"—a type of machine learning that is based on artificial neural networks—outperform humans, even experts, in the classification of pigmented skin lesions. In this interview with i3 Health, Philipp Tschandl, member of the Vienna Dermatologic Imaging Research (ViDIR) Group of the Medical University of Vienna's Department of Dermatology, discusses the ...

Top Oncology Stories

Wednesday, June 19, 2019
Halichondrins, natural products isolated from marine sponges, have demonstrated antitumor activity both in live mice and in human cancer cell cultures. Previously, the limited supp...
Wednesday, June 19, 2019
​Philipp Tschandl, MD, PhD, and colleagues found that current artificial intelligence (AI) algorithms that use "deep learning"—a type of machine learning that is based on artif...
Tuesday, June 18, 2019
Pembrolizumab (Keytruda®, Merck) has received accelerated FDA approval for patients with metastatic small cell lung cancer (SCLC) experiencing disease progression during or aft...
Tuesday, June 18, 2019
A biomarker that can be identified by blood test was discovered to be a potential indicator of prognosis for human papillomavirus (HPV)-associated oropharyngeal cancer."Head...
Monday, June 17, 2019
Pancreatic ductal adenocarcinoma (PDAC), which is for the most part resistant to chemotherapy and lacks effective treatments, is the fourth leading cause of cancer-related deat...

Expert Perspectives

​Philipp Tschandl, MD, PhD, and colleagues found that current artificial intelligence (AI) algorithms that use "deep learning"—a type of machine learning that is based on artificial neural networks—outperform humans, even expe...
Non-small cell lung cancer (NSCLC) has traditionally had a poor prognosis in terms of overall survival. This dismal outcome is changing, however: the phase 1 KEYNOTE-001 study found that pembrolizumab (Keytruda®, Merck) sub...
Recently, the FDA approved ruxolitinib (Jakafi®, Incyte Corporation), a JAK1/JAK2 inhibitor, for the treatment of steroid-refractory acute graft-versus-host disease (GVHD). A potentially life-threatening condition, GVHD is a c...
Receiving a cancer diagnosis can be devastating, confusing, and overwhelming. It is important for oncologists to be thorough in explaining the treatment process to patients. In this interview with i3 Health, Carla Casulo, M...
This week, the FDA approved lenalidomide (Revlimid®, Celgene Corporation) in combination with a rituximab product for relapsed/refractory follicular lymphoma (FL) and relapsed/refractory marginal zone lymphoma (MZL). In this i...

Original Research

​In the constantly evolving field of cancer immunotherapy, it is crucial that community practitioners keep abreast of the latest advances. In this interview with i3 Health, Latha Shivakumar, PhD, CHCP, discusses her poster pre...
Over the past few years, the treatment options for castration-resistant prostate cancer (CRPC) have increased to include novel hormone therapies, second-generation taxanes, immunotherapy, and bone-targeted and bone metastasis-t...
​At the Oncology Nursing Society (ONS) 44th Annual Congress in Anaheim, California, in April 2019, i3 Health surveyed oncology nurses regarding their educational needs on a variety of topics, including immune checkpoint inhibi...
Immune checkpoint inhibition is a form of immunotherapy that blocks checkpoint proteins on immune cells, boosting the body's immune response against cancer cells. Checkpoint inhibitors such as pembrolizumab (Keytruda®, Merck), ...
​Cyclin dependent kinase (CDK)4/6 inhibitors have produced tremendous advances in the treatment of hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer through their targetin...

© Copyright 2019 i3 Health. All rights reserved.